Image de couverture de livre

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Alan Faraj, Joakim Nyberg, Grant E. Blouse, Tom Knudsen, Ulrika S. H. Simonsson
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX‐FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis
par: Sjoerd F. Koopman, et autres
Publié: (2025)

Erratum to “Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX ‐ FP Prophylaxis in Hemophilia B: A Repeated Time‐to‐Event Analysis”
Publié: (2025)

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events
par: Thanh Phuong Pham Nguyen, et autres
Publié: (2024)

Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time‐To‐Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A
par: Nancy Wong, et autres
Publié: (2025)

Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation
par: Shin‐Yi Lin, et autres
Publié: (2025)

Bemnifosbuvir: An HCV NS5B Inhibitor With Multiple Modes of Action
par: Carolin Zitzmann, et autres
Publié: (2026)

Response to Letters Regarding “Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors”
par: Léonard Laurent, et autres
Publié: (2025)

Capability Development in the European Medicines Regulatory Network—A European Learning Needs Analysis and Survey Study
par: Naomi Beard, et autres
Publié: (2025)

Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
par: Hongmei Duan, et autres
Publié: (2025)

Ocular Complications of SGLT ‐2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in T2DM Treatments: A Retrospective Real‐World Cohort Study
par: Lee‐Yuan Lin, et autres
Publié: (2025)

Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
par: John D. Davis, et autres
Publié: (2024)

A Consideration of Exploratory Approaches to Comedications Associated With Immune‐Related Adverse Events during Immune Checkpoint Inhibitor Therapy
par: Yoshihiro Noguchi, et autres
Publié: (2025)

Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor
par: Manthena V. S. Varma, et autres
Publié: (2025)

Model‐Informed Drug Development‐Based Bridging from Subcutaneous to Intravenous Secukinumab Dosing: Approval in Psoriatic Arthritis and Axial Spondyloarthritis
par: Thomas Dumortier, et autres
Publié: (2025)

Oral and Intravenous Metronidazole Concentrations in Facial Artery Musculomucosal Flap, Buccal Submucosa, and Subcutaneous Tissue—A Randomized Clinical Microdialysis Study
par: Pelle Hanberg, et autres
Publié: (2025)

A Comparative Clinical Pharmacology Analysis of FDA‐Approved Targeted Covalent Inhibitors vs. Reversible Inhibitors in Oncology
par: Huy X. Ngo, et autres
Publié: (2024)

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data
par: Maria J. Alfonso Arvez, et autres
Publié: (2025)

Algorithmic Identification of Treatment‐Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease
par: Anna L. Silverman, et autres
Publié: (2024)

Insights Into Aldosterone Regulation Through Pharmacokinetic–Pharmacodynamic Modeling of an Aldosterone Synthase Inhibitor
par: Javiera Cortés‐Ríos, et autres
Publié: (2025)

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis
par: Antonio Tursi, et autres
Publié: (2026)

BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of Vigibase
par: Aurélie Cabannes‐Hamy, et autres
Publié: (2025)

Efficacy and Safety of Janus Kinase Inhibitors in Patients with Vitiligo: A Systematic Review and Meta‐Analysis
par: Fan Huang, et autres
Publié: (2024)

The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression
par: Gia Han Le, et autres
Publié: (2026)

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
par: Jatinder Kaur Mukker, et autres
Publié: (2025)

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme
par: Chin Hang Yiu, et autres
Publié: (2026)

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems
par: Janne T. Backman
Publié: (2025)

Major Adverse Cardiac Events with Ondansetron: A Systematic Review
par: Michael Cristian Garcia, et autres
Publié: (2025)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
par: Natalia Sauer, et autres
Publié: (2026)

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects
par: Emma C. Bernsen, et autres
Publié: (2025)

Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
par: Tania Payo‐Serafín, et autres
Publié: (2024)

A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
par: Xuewen Ma, et autres
Publié: (2024)

Risk of Hypoglycemia Associated With Concomitant Use of Insulin Secretagogues and ACE Inhibitors in Adults With Type 2 Diabetes: A Systematic Review
par: Patricia Y. Chu, et autres
Publié: (2024)

Prenatal and Early Childhood Exposure to Antibiotics or Gastric Acid Inhibitors and Increased Risk of Epilepsy: A Nationwide Population‐Based Study
par: Unnur Gudnadottir, et autres
Publié: (2025)

First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS‐986308: A Renal Outer Medullary Potassium Channel Inhibitor
par: Sharif I. Soleman, et autres
Publié: (2024)

Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
par: Ashley N. Springer, et autres
Publié: (2025)

FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
par: Emanuel Raschi, et autres
Publié: (2025)

TMS and EEG Pharmacodynamic Effects of a Selective Sphingosine‐1‐Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects
par: Catherine M. K. E. de Cuba, et autres
Publié: (2024)

Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence‐Based Review on Emerging Clinical Data
par: Yujing Li, et autres
Publié: (2024)

Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement
par: Irina Kareva, et autres
Publié: (2025)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
par: Teng‐Li Lin, et autres
Publié: (2026)